(AOF) – DMS Group, a European medical imaging medtech, today presents its strategic plan called “Imaging 2027” with the ambition of becoming a key player in medical imaging in Europe in the next five years. Imaging 2027 is based on three strategic axes: Innovation, organic growth and sector consolidation. As part of Imaging 2027, DMS Group has set ambitious goals for 2027. It wants to reach a new growth milestone and is aiming for a turnover of at least 60 million euros, against 37.1 million in 2021 by 2027.
Over the past few years, DMS Group has based its development on its radiology tables, Platinum and Optima, integrating the Adam imaging software suite which includes artificial intelligence (AI) based image processing capabilities and a most efficient innovative patient flow management (workflow) on the market.
DMS group has embarked on the development of two new high-end imaging solutions, a radiology mobile and an operating theater arch, which will be manufactured in France and will strengthen the DMS Imaging product range by 2024 and 2025.
As part of this project, DMS Group has entered into a strategic partnership with the Australian company Micro-X for the supply of cold cathode X-ray tubes, a leading innovative technological solution, the first integration tests of which are in progress. Classes.
Finally, in bone densitometry, DMS Group is aiming to develop a new range of bone densitometers in the medium and high-end market segments, with greater added value and with a high level of scientific validation. The Group aims to position these new solutions on the American market, the world’s largest bone densitometry market, by 2025.
The group also wishes to forge new strategic and/or capital alliances in order to create a real French and European sector in medical imaging (horizontal and vertical consolidation). In addition, the group wishes to strengthen its shareholding and acquire one or more reference shareholders to accompany and support its development.
As part of Imaging 2027, DMS Group wishes to reach a new growth milestone and is aiming for a turnover of at least 60 million euros, against 37.1 million in 2021 (including 36.3 million for the division DMS Imaging). It also intends to improve its profitability and is targeting an Ebitda margin of 14% against 5.1% in 2021 (including 6.8% for the DMS Imaging division). These objectives relate solely to organic growth.
Finally, to support the group’s developments within the framework of the Imaging 2027 plan, the new DMS Group board of directors wanted to set up a strategic committee for the DMS Imaging division with high-level personalities from the world of imaging. medical and business strategy specialists in this sector.
Receive our latest news
Every morning, the information to remember on the financial markets.
We want to thank the writer of this write-up for this amazing material
DMS Group unveils its “Imaging 2027” strategic plan
Find here our social media profiles as well as other pages that are related to them.https://www.ai-magazine.com/related-pages/